Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the most important component of systemic therapy for hormone-responsive breast cancer. Unfortunately, endocrine-resistant ER-positive disease represents up to one-quarter of all breast cancers and a number of different mechanisms have been implicated in endocrine resistance, either intrinsic, occurring de novo at the initial exposure to endocrine therapies or acquired, occurring after an initial response to therapy. In the present work a number of molecular mechanisms accounting for intrinsic and acquired resistance to hormonal therapies have been reviewed and the most promising strategies to overcome endocrine resistance have been highlighted.

Overcoming Endocrine Resistance in Breast Cancer / R. A., Madaio; G., Spalletta; L., Cravello; M., Ceci; L., Repetto; Naso, Giuseppe. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - STAMPA. - 10:5(2010), pp. 519-528. [10.2174/156800910791517226]

Overcoming Endocrine Resistance in Breast Cancer

NASO, Giuseppe
2010

Abstract

Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the most important component of systemic therapy for hormone-responsive breast cancer. Unfortunately, endocrine-resistant ER-positive disease represents up to one-quarter of all breast cancers and a number of different mechanisms have been implicated in endocrine resistance, either intrinsic, occurring de novo at the initial exposure to endocrine therapies or acquired, occurring after an initial response to therapy. In the present work a number of molecular mechanisms accounting for intrinsic and acquired resistance to hormonal therapies have been reviewed and the most promising strategies to overcome endocrine resistance have been highlighted.
2010
breast cancer; estrogen receptor; hormone resistance
01 Pubblicazione su rivista::01a Articolo in rivista
Overcoming Endocrine Resistance in Breast Cancer / R. A., Madaio; G., Spalletta; L., Cravello; M., Ceci; L., Repetto; Naso, Giuseppe. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - STAMPA. - 10:5(2010), pp. 519-528. [10.2174/156800910791517226]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/103297
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact